Shannon Eaker, PhD, Cytiva, Marlborough, MA, provides an overview of the significance of digitization in cell and gene therapy (CGT) manufacturing. Scaling up manufacturing remains a major barrier and digitization may be a solution to the issue. Whilst digitized standard operating procedures (SOPs) and batch records can streamline the manufacturing process, the low adoption rate due to the need for increased staff training requires to be addressed, especially when other stakeholders including regulatory authorities will digitize their records. The use of artificial intelligence (AI) can additionally enable efficient data collection and mining, which will be of particular use in the autologous setting. This interview took place at Advanced Therapies Week 2022.